# OnCo record msi-high-colorectal (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/msi-high-colorectal/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "msi-high-colorectal" ;
  schema:name "Mismatch-repair deficient (MSI-high) colorectal cancer"@en ;
  schema:alternateName "dMMR colorectal cancer"@en, "MSI-H colorectal cancer"@en, "Microsatellite unstable colorectal cancer"@en, "Lynch-associated colorectal cancer"@en, "Hypermutated colorectal cancer"@en ;
  schema:description "Mismatch-repair deficient bowel cancer has lost its DNA spell-checker, so it carries thousands of mutations that the immune system can recognise. Immunotherapy alone controls most metastatic cases for years and makes most localised tumours disappear before surgery, sometimes so completely that no surgery is needed."@en ;
  schema:url <https://onco.cc/cancers/msi-high-colorectal/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Microsatellite_instability> ;
  schema:citation <https://en.wikipedia.org/wiki/Microsatellite_instability>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/colorectal-screening/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/wrn/>, <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/aspirin/> ;
  onco:pathways <https://onco.cc/pathways/colorectal-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/clinical-complete-response/>, <https://onco.cc/terms/organ-preservation/>, <https://onco.cc/terms/cms-subtypes/> ;
  onco:trials <https://onco.cc/trials/keynote-177/>, <https://onco.cc/trials/checkmate-8hw/>, <https://onco.cc/trials/niche-2/>, <https://onco.cc/trials/atomic/>, <https://onco.cc/trials/azur-1/>, <https://onco.cc/trials/nct05855200/>, <https://onco.cc/trials/nct07412613/>, <https://onco.cc/trials/nct06686576/>, <https://onco.cc/trials/nct06640049/> ;
  onco:people <https://onco.cc/people/thierry-andre/>, <https://onco.cc/people/luis-diaz/>, <https://onco.cc/people/andrea-cercek/>, <https://onco.cc/people/heinz-josef-lenz/> ;
  onco:pipeline <https://onco.cc/ideas/idea-bio1-wrn-msi-programme/>, <https://onco.cc/drugs/eik1005/>, <https://onco.cc/drugs/cadonilimab/>, <https://onco.cc/trials/nct07412613/>, <https://onco.cc/trials/nct06686576/>, <https://onco.cc/trials/nct05855200/>, <https://onco.cc/ideas/idea-prev-lynch-frameshift-vaccine-rct/>, <https://onco.cc/ideas/idea-prev-lynch-aspirin-implementation/> ;
  onco:standardOfCare <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/trials/keynote-177/>, <https://onco.cc/trials/checkmate-8hw/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/trials/niche-2/>, <https://onco.cc/trials/atomic/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/trials/azur-1/>, <https://onco.cc/terms/organ-preservation/>, <https://onco.cc/terms/clinical-complete-response/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/drugs/aspirin/>, <https://onco.cc/technologies/colorectal-screening/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/chemoprevention/> .